Precision Biosciences INC Form 4 insider transactions

Michael Amoroso, President and CEO of Precision BioSciences, reports the vesting and sale of common stock to cover tax obligations.

Alan List, Chief Medical Officer of Precision BioSciences, reports the vesting and sale of common stock to cover tax obligations.

J. Jefferson Smith, Chief Research Officer of Precision BioSciences, acquired 31,343 restricted stock units on April 18, 2024, according to a Form 4 filing.

Michael Amoroso, CEO of Precision BioSciences, reports the acquisition of 111,217 restricted stock units.

Dario Scimeca, General Counsel and Secretary of Precision BioSciences, was granted 25,277 restricted stock units (RSUs) on April 18, 2024, vesting annually starting January 20, 2025.

Chief Financial Officer of Precision BioSciences, John Alexander Kelly, reports the acquisition of 41,705 restricted stock units.